Compare Gilead Sciences, Inc. (GILD) vs Veritone Inc (VERI) Price & Performance

Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.

Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.

Veritone (VERI) trades at $1.005, down 6.07% in the last session, reflecting significant investor concern. The stock shows a bearish technical signal with moving averages indicating strong selling pressure. Fundamentally, the company reported a net loss of $111.73M on $92.19M revenue for 2025, with a negative net income margin of -123.76%, though it maintains a high gross margin of 68.52%. Recent news is dominated by multiple class-action lawsuits alleging revenue overstatements, with key deadlines approaching in July 2026.

The outlook is highly challenged. While analyst consensus shows a split between Buy and Hold ratings, severe financial losses, negative cash flow from operations, and ongoing litigation create substantial downside risk. The company's ability to achieve profitability and manage legal liabilities remains the critical factor for any potential recovery in shareholder value.